The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Phase II study of glofitamab in patients with R/R LBCL
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the design and results of the pivotal Phase II trial evaluating glofitamab in patients with relapsed/refractory (R/R) aggressive large B-cell lymphoma (LBCL) who have been treated with CAR-T therapy (NCT03075696). The trial reported high and durable complete remission rates. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Funding, research & consulting: Novartis, Roche, Kite/Gilead, BMS, Takeda
